首页> 中文期刊> 《疑难病杂志》 >巨噬细胞可溶性CD163与自身免疫疾病关系的研究进展

巨噬细胞可溶性CD163与自身免疫疾病关系的研究进展

         

摘要

Soluble CD163 is serum soluble CD163 secreted by monocytes/macrophages,it exists in serum and other tissues,associated with inflammation,now it considered to be the specificity activation markers in monocyte/ macrophage.When acute and chronic inflammation occurs,CD163 fall off from the surface of the mononuclear macrophage membrane and the formation of sCD163.When sCD163 released into peripheral blood,the expression was increased,and it correlated with the concentration.The concentration of sCD163 in peripheral blood can be used to determine the development of the disease.The higher the concentration of sCD163,the faster the disease progresses.The expression of sCD163 was correlated with autoimmune disease.The concentrations of sCD163 in serum and histological can be used as active indicators of disease to predict prognosis.Therefore,the clinical study by focusing on the concentration of sCD163,judging the activity and the degree of autoimmune disease,can reduce the incidence and pain of patients,improve the prognosis.%可溶性CD163是由单核细胞/巨噬细胞分泌的血清可溶性CD163(sCD163),存在于血清及其他组织液中,与炎性反应的发生相关,被认为是单核细胞/巨噬细胞活化的特异性标记物.当出现急慢性炎性反应时,CD163从单核巨噬细胞膜表面脱落形成sCD163,通过可溶形式释放到外周血中,使其表达增加且与预后相关,通过外周血中的s CD163浓度可判断出病情发展情况,浓度越高患者疾病进展速度越快.sCD163的表达与各种自身免疫疾病关系密切,血清及组织液sCDI63的浓度可作为疾病活动的发展指标并进行预后判断.因此,临床通过关注sCD163的浓度,判断自身免疫疾病的发展程度,能够降低其发生率,改善患者预后,减轻患者的痛苦.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号